• Diabetes Testing is the Largest Biosensors Market in Medical Applications

    Nov 8, 2016, 02:59 AM by Michael Croft
    ALBANY, NY, UNITED STATES - Nov 8, 2016 - Biosensors are the devices used for the detection of analyte and combines physiological detector with biological components
    Full story
  • BOC Sciences Published New Chemicals with Rare Access

    Nov 8, 2016, 01:02 AM by Michael Croft
    LONG ISLAND CITY, NY, UNITED STATES - Nov 8, 2016 - BOC Sciences is under tight construction on its inhibitor and main products. Till present, good feedback like searching being facilitated has been reflected from regular customers, by which the company is much more motivated to build the site a better online shop for chemicals
    Full story
  • Understanding Africas Diverse Gene Pool Can Help Fight Lifestyle Diseases

    Nov 7, 2016, 10:41 AM by Michael Croft
    The Conversation | Cracking genetic responses to the changing environment in Africa would open a new frontier in the drive against rising non-communicable diseases on the continent.
    Full story
  • Geriatric Population Rise makes Long Term Care Market to Grow Steadily

    Nov 7, 2016, 06:10 AM by Michael Croft
    ALBANY, NY, UNITED STATES - Nov 7, 2016 - Long term care (LTC) service contains a variety of services provided by nursing homes, day care centres, home health agencies and from family or friends
    Full story
  • Equine Veterinary Services Market is Observed to be a Multi-Billion Dollar Industry

    Nov 7, 2016, 05:07 AM by Michael Croft
    ALBANY, NY, UNITED STATES - Nov 7, 2016 - Global equine veterinary market is observed to be a multi-billion dollar industry that consists of various equine activities such as horse racing, competitive riding and leisure
    Full story
  • Supercomputing the p53 Protein as a Promising Anticancer Therapy

    Nov 4, 2016, 16:14 PM by Michael Croft
    Texas Advanced Computing Center | Computational biophysicist Rommie Amaro is using the Stampede supercomputer at TACC to model the largest atomic level system of the tumor suppression protein p53 to date - over 1.5 million atoms. The simulations identify new "pockets" to reactivate p53 which would be a tremendous boost for future anti-cancer drug discovery.
    Full story
  • Tackling the Organizational Challenges Slowing Biotech

    Nov 4, 2016, 13:20 PM by Michael Croft

    Bio-IT World  “How do you change the way scientists operate in a fundamental way to win them over?” Matthew Trunnell, CIO at the Fred Hutchinson Cancer Institute, asked the crowd at the Converged IT Summit* last week in San Diego during his opening keynote. While there were plenty of the talks wading into the weeds of how to build and structure data centers, much of the conversation at the Summit tackled the more amorphous problems plaguing bio-IT today: building a community that shares data and incentivizes collaboration.

    Full story
  • Weill Cornell Medicine and the New York Genome Center Awarded NCI Grant to Create Genomic Data Center

    Nov 3, 2016, 11:15 AM by Michael Croft

    Bio-IT World News Brief | Weill Cornell Medicine and the New York Genome Center  were recently awarded a federal grant from the National Cancer Institute to support a joint cancer genomics data center for the research and clinical interpretation of tumors. The grant will provide funding of $490,000 per year over the next five years.

    Full story
  • Flatiron Health And Foundation Medicine Partner To Launch Clinico-Genomic Database

    Nov 3, 2016, 09:53 AM by Michael Croft
    Diagnostics World News | Flatiron and Foundation Medicine today announced the launch of a clinico-genomic database designed to help researchers and biopharmaceutical partners accelerate the development of targeted therapeutics and immunotherapies to treat cancer. the clinico-genomic database, containing information on nearly 20,000 patients, is one of the largest and most comprehensive information efforts of its kind in oncology.
    Full story
  • New Data Show Power Limits of Bluebird’s Gene Therapy For Blood Diseases

    Nov 3, 2016, 09:48 AM by Michael Croft
    Xconomy | Bluebird Bio is releasing new data this morning that speak to both the potential and the limitations of a gene therapy it's been developing for two deadly blood diseases: sickle cell disease and beta-thalassemia.
    Full story
  • The Pistoia Alliance Calls for Greater Collaboration on Wearable Devices in R&D

    Nov 2, 2016, 09:43 AM by Michael Croft
    LONDON, UNITED KINGDOM - Nov 2, 2016 -  The Pistoia Alliance, a global, not-for-profit alliance that works to lower barriers to innovation in life sciences R&D, is calling on the pharmaceutical industry to support greater collaboration around wearable device initiatives
    Full story
  • Recipharm invests in its Italian API facility

    Nov 2, 2016, 07:14 AM by Michael Croft
    PADERNO DUGNANO, ITALY - Nov 2, 2016 - Recipharm, the contract development and manufacturing organisation (CDMO), has announced an investment of over €1
    Full story
  • Repositive Announce Launch of Microbiome Data Collection

    Nov 2, 2016, 05:34 AM by Michael Croft
    CAMBRIDGE, UNITED KINGDOM - Nov 2, 2016 - Repositive, a software company developing novel tools to improve discovery and access to human genomic research data, has expanded its Specialised Data Collections, with the addition of microbiome data
    Full story
  • Optibrium And Collaborative Drug Discovery Integrate StarDrop With CDD Vault

    Nov 1, 2016, 15:35 PM by Michael Croft

    Bio-IT World News Brief | Optibrium and Collaborative Drug Discovery announced a collaboration to integrate the StarDrop and CDD Vault platforms. This creates a connection in real time between project data, securely held and managed in CDD Vault, and StarDrop’s unique compound design and optimization capabilities. 

    Full story
  • Young Scientists Ditch Postdocs for Biotech Start-Ups

    Nov 1, 2016, 12:01 PM by Michael Croft
    Nature News & Comment | Many biologists are founding their own firms as venture capitalists show increased interest in science.
    Full story
  • Danforth Plant Science Center Develops Versatile Field Phenotyping to Benefit Farmers

    Nov 1, 2016, 11:54 AM by Michael Croft
    ST. LOUIS, MO, UNITED STATES - Nov 1, 2016 -                            Solar-powered PheNode is set for investment stage.Researchers at the Donald Danforth Plant Science Center, a not-for-profit research institute with a mission to improve the human condition through plant science, are leveraging expertise in crop phenotyping with the development of the PheNode, a 'smart', farm-ready, solar-powered environmental sensor and phenotyping station for crops
    Full story
  • FactBio Announces Improvements to the Kusp Data Curation Platform

    Nov 1, 2016, 05:55 AM by Michael Croft
    CAMBRIDGE, UNITED KINGDOM - Nov 1, 2016 - FactBio, has launched Kusp 1.1, an update to its data curation platform which sees a number of new key features added
    Full story
  • Smarter ELNs and Smarter Labs Make for Smarter Science

    Oct 31, 2016, 16:10 PM by Michael Croft

    Bio-IT World | New technology, new laws and regulations, and more cumbersome "Big Data" have together caused the standard, traditional electronic lab notebook (ELN) to obsolesce.  But some experts believe new digital-transformation technology—including the Internet of Things and cloud computing—will allow for enhanced ELNs that can address today's clinical pain points of efficiency, ROI, scientific contextual consistency, and risk reduction.

    Full story
  • Mark Zuckerberg Is Funding a Facebook for Human Cells

    Oct 31, 2016, 15:00 PM by Michael Croft
    MIT Technology Review | The billionaire is the first major donor to back the idea of creating an atlas of all human cells.
    Full story
  • Third Rock Ventures One of Biotechs Daring Investors Raises $616M For More Startups

    Oct 31, 2016, 11:52 AM by Michael Croft
    Forbes | Biotech venture capital is supposed to be the highest-risk/highest-reward type of investment there is. But many biotech VCs are actually pretty conservative, hesitant to wager on edgy science that might take a decade to pay off. Not Third Rock Ventures.
    Full story